First Patient Dosed in Early Trial Evaluating Provention’s PRV-3279 for SLE
Provention Bio has dosed the first lupus patient enrolled in the Phase 1b/2 trial testing the safety and pharmaceutical properties of its experimental B-cell-targeted therapy PRV-3279. Results from the first part of the PREVAIL study, done in healthy volunteers, are expected for the first half of 2020.